The new clinical data shows that Johnson & Johnson’s pharmaceutical department has confirmed that its candidate COVID-19 vaccine can stimulate an immune response for more than two months or 71 days among 805 study participants.
By publishing Press release And published on New England Journal of Medicine, The company said that this vaccine called Ad26.COV2.S triggered an immune response against COVID-19 antibodies after a single dose.
Experts’ evaluation of vaccination work
CDC officials ensure the safety of the COVID-19 vaccine despite adverse reactions
Does New York call it a COVID-19 vaccine to draw the line?
The former head of the FDA highly thought that the new COVID-19 mutation had been marketed in the United States.
Johnson & Johnson claims that only one dose of Ad26.COV2.S will produce strong neutralizing antibodies in more than 90% of its clinical trial volunteers.
These neutralizing antibodies can prevent viral proteins from binding to human cells. The two-dose regimen was less reactive, but triggered twice as many antibodies.
The upcoming Phase 3 clinical trial (the final stage of vaccine testing) will determine whether the second dose provides other efficacy or lasting benefits primarily in the elderly.
“Although all ongoing Phase 3 studies of other Covid-19 vaccines have evaluated two-dose regimens, a single dose of Ad26.COV2.S will cause a strong humoral response in most vaccinators, and the presence of S-binding and Neutralization Regardless of age or vaccine dose, more than 90% of participants contained antibodies.”
Five serious adverse side effects were reported, including a participant who was temporarily hospitalized due to fever. Other common adverse reactions are migraine, myalgia, fatigue and pain at the injection site.
The study authors said that due to the US government’s efforts to allocate the doses of available vaccines to the initial population, a single-dose vaccine that proved effective against COVID-19 exposure “has obvious logistical advantages over two-dose vaccines, especially during a pandemic.”
This may be due to the method of making the vaccine. CNN notes Johnson & Johnson’s candidates did not use mRNA to communicate with human cells and make them fight against COVID-19 pathogens, but used a weak virus common virus called adenovirus 26 to stimulate an immune response, thereby helping the body recognize and fight COVID-19 Particles. .
Johnson & Johnson specifically acknowledges that the lack of minority groups is a representative characteristic of the research participants.
Although the results of the early trials are encouraging, the New York Times write The company is falling behind in production, while the federal government is waiting for more than 60 million doses. According to reports, the company may catch up with production by March.
According to the recommendations of the Chinese Center for Disease Control and Prevention, Wuhan may have reported many COVID-19 cases, which have occurred 10 times.
New variants of the British coronavirus: what you need to know
From the laboratory to the upper arm: how to make the COVID-19 vaccine a reality
5,000 body bags and 60 mortgage trucks were sent to the vandalized California